Shares of Orexigen Therapeutics Inc. (NASDAQ:OREX) hit a new 52-week low during trading on Monday . The stock traded as low as $3.42 and last traded at $3.42, with a volume of 150,675 shares trading hands. The stock had previously closed at $3.51.

Separately, Zacks Investment Research upgraded shares of Orexigen Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, April 21st. One equities research analyst has rated the stock with a sell rating and eight have issued a hold rating to the stock. The company has a consensus rating of “Hold” and an average price target of $2.61.

The company has a 50 day moving average price of $4.32 and a 200 day moving average price of $7.76. The stock’s market capitalization is $48.03 million.

Orexigen Therapeutics (NASDAQ:OREX) last released its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.02. The firm had revenue of $5 million for the quarter, compared to the consensus estimate of $7.78 million. During the same quarter in the prior year, the company posted ($0.14) EPS. The firm’s revenue was up 16.3% on a year-over-year basis. Analysts predict that Orexigen Therapeutics Inc. will post ($5.61) EPS for the current year.

Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.